Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry

被引:24
作者
ter Heine, R. [1 ]
Rosing, H. [1 ]
van Gorp, E. C. M. [1 ]
Mulder, J. W. [1 ]
Beijnen, J. H. [1 ]
Huitema, A. D. R. [1 ]
机构
[1] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
关键词
Etravirine; TMC125; LC-MS/MS; Pharmacology; TDM; EXPERIENCED HIV-1-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS; PLACEBO-CONTROLLED TRIAL; PROTEASE INHIBITORS; ANTIRETROVIRAL DRUGS; DOUBLE-BLIND; EFFICACY; SAFETY;
D O I
10.1016/j.jpba.2008.10.040
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
For the quantification of the novel non-nucleoside reverse transcriptase inhibitor etravirine in human plasma, dried blood spots and peripheral blood mononuclear cell (PBMC) lysate, an assay was developed and validated, using liquid chromatography coupled with tandem mass spectrometry. Etravirine was extracted from plasma by means of protein precipitation with a mixture of methanol and acetonitrile using only 50 mu L plasma. Extraction from dried blood spots was performed with a one-step extraction with a mixture of methanol, acetonitrile and 0.2 M zinc sulphate in water (1:1:2, v/v/v) and extraction from cell lysate was performed in 50% methanol in water. Chromatographic separation was performed on a reversed phase C18 column (150 mm x 2.0 mm, particle size 5 mu m) with a quick stepwise gradient using an acetate buffer (pH 5)and methanol,at a flow rate of 0.25 mL/min. (13)C(6)-efavirenz was used as an internal standard. The analytical Fun time was only 10 min. The triple quadrupole mass spectrometer was operated in the positive ion-mode and multiple reaction monitoring was used for drug quantification. The method was validated over a range of 25-5000 ng/mL in plasma, 50-10,000 ng/mL in dried blood spots and a range of 5-2500 ng/mL in PBMC lysate. Accuracies ranged from 89% to 106% in plasma, from 94% to 109% in dried blood spots and from 91% to 105% in PBMC lysate. Precisions at the all concentration levels ranged from 1.9% to 14% in plasma, 4.7% to 20% in dried blood spots and from 3.1% to 11% in PBMC lysate. The bioanalytical assay was successfully incorporated with previously developed assays for the determination of all currently approved Pls and NNRTIs in plasma and dried blood spots and it is now applied for therapeutic drug monitoring and pharmacological research in HIV-infected patients treated with etravirine. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:393 / 400
页数:8
相关论文
共 10 条
[1]   Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry [J].
Colombo, S ;
Beguin, A ;
Telenti, A ;
Biollaz, J ;
Buclin, T ;
Rochat, B ;
Decosterd, LA .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 819 (02) :259-276
[2]   Practical guidelines to interpret plasma concentrations of antiretroviral drugs [J].
Kappelhoff, BS ;
Crommentuyn, KML ;
de Maat, MMR ;
Mulder, JW ;
Huitema, ADR ;
Beijnen, JH .
CLINICAL PHARMACOKINETICS, 2004, 43 (13) :845-853
[3]   Intracellular accumulation of human immunodeficiency virus protease inhibitors [J].
Khoo, SH ;
Hoggard, PG ;
Williams, I ;
Meaden, ER ;
Newton, P ;
Wilkins, EG ;
Smith, A ;
Tjia, JF ;
Lloyd, J ;
Jones, K ;
Beeching, N ;
Carey, P ;
Peters, B ;
Back, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3228-3235
[4]  
KNUDSEN RC, 2007, CDC GUIDELINES SHIPM
[5]   Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial [J].
Lazzarin, Adriano ;
Campbell, Thomas ;
Clotet, Bonaventura ;
Johnson, Margaret ;
Katlama, Christine ;
Moll, Arend ;
Towner, William ;
Trortier, Benoit ;
Peeters, Monika ;
Vingerhoets, Johan ;
de Smedt, Goedele ;
Baeten, Benny ;
Beets, Greet ;
Sinha, Rekha ;
Woodfall, Brian .
LANCET, 2007, 370 (9581) :39-48
[6]   Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial [J].
Madruga, Jose Valdez ;
Cahn, Pedro ;
Grinsztejn, Beatriz ;
Haubrich, Richard ;
Lalezari, Jacob ;
Mills, Anthony ;
Pialoux, Gilles ;
Wilkin, Timothy ;
Peeters, Monika ;
Vingerhoets, Johan ;
de Smedt, Goedele ;
Leopold, Lorant ;
Trefiglio, Roberto ;
Woodfall, Brion .
LANCET, 2007, 370 (9581) :29-38
[7]  
Scholler-Gyure M, 2008, BR J CLIN PHARM
[8]   Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry [J].
ter Heine, R. ;
Rosing, H. ;
van Gorp, E. C. M. ;
Mulder, J. W. ;
van der Steeg, W. A. ;
Beijnen, J. H. ;
Huitema, A. D. R. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 867 (02) :205-212
[9]   Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry [J].
ter Heine, Rob ;
Aiderden-Los, Carolien G. ;
Rosing, Hilde ;
Hillebrand, Michel J. X. ;
van Gorp, Eric C. M. ;
Huitema, Alwin D. R. ;
Beijnen, Jos H. .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2007, 21 (15) :2505-2514
[10]  
U.S. Food and Drug Administration, 2007, GUID IND BIOAN METH